PLRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
23.9M
+9.6%
21.8M
-7.7%
23.6M
-16.6%
28.3M
-38.0%
45.6M
R&D
16.7M
+23.1%
13.6M
-12.8%
15.6M
-13.1%
17.9M
-44.3%
32.2M
SG&A
7.1M
-12.9%
8.2M
+2.5%
8.0M
-22.6%
10.3M
-22.9%
13.4M
Operating Income
-23862000
-9.6%
-21772000
+7.7%
-23577000
+16.6%
-28269000
+38.0%
-45592000
EBITDA
-23613000
-9.8%
-21508000
+7.3%
-23212000
+16.6%
-27833000
+38.3%
-45145000
Net Income
-22371000
-11.6%
-20040000
+15.0%
-23577000
+10.4%
-26301000
+39.3%
-43300000
EPS (Basic)
$-0.36
-12.5%
$-0.32
+15.8%
$-0.38
+11.6%
$-0.43
+39.4%
$-0.71
EPS (Diluted)
$-0.36
-12.5%
$-0.32
+15.8%
$-0.38
+11.6%
$-0.43
+39.4%
$-0.71
Shares (Diluted)
61.9M
+0.2%
61.8M
+0.6%
61.5M
+0.1%
61.4M
+0.0%
61.4M
Pliant Therapeutics (PLRX) โ€” Financials